|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Lactobacilli,bifi dobacteria and E.coli nissle induce pro-and anti-inflammatory cytokines in peripheral blood mononuclear cells显示文摘AIM: To investigate whether the stimulation of peripher- al blood mononuclear cells (PBMNC) with the cell debris and cell extraction of different probiotic strains is similar or species specifi c. METHODS: Three strains of bifi dobacteria, 4 strains of lactobacilli, and E. coli nissle were sonicated and centri- fuged in order to divide them into cell extract and cell debris. PBMNC were separated by density gradient and incubated for 36 h with either the cell debris or the cell extract of single strains of probiotic bacteria in doses from 102 to 108 CFU/mL. Cell supernatants were taken and interleukin (IL)-10, IL-1β, and tumor necosis factor (TNF)-α were determined by ELISA. RESULTS: Depending on the species super-family, the strains had different stimulation patterns. Except for both L. casei strains, the cell extract of bifidobacteriaand lactobacilli had less stimulating capacity than cell debris, whereas the cell extract of E. coli nissle had simi- lar stimulating properties to that of the cell debris of the strain and significantly more stimulating capacity than that of bifi dobacteria and lactobacilli. The cell debris of bifi dobacteria stimulated more cytokine release than the cell debris of lactobacilli. The cell debris of lactobacilli did not have a stimulating capacity when lower concentra- tions were used. Neither cell extraction nor cell debris had an inhibitory effect on the production of the tested cytokines by stimulated PBMNC. CONCLUSION: The incubation of probiotic strains, which have been used in clinical trials for inflammatory diseases, with immunocompetent cells leads to different species specifi c reactions. High IL-10 response to cell de- bris of bifi dobacteria and E. coli nissle can be found. This corresponds to positive effects of bifi dobacteria and E. coli nissle in clinical trials for inflammatory bowel disease compared to negative outcomes obtained with lactoba- cilli. | Ulf Helwig Karen M Lammers Fernando Rizzello Patricia Brigidi Verena Rohleder Elisabetta Caramelli Paolo Giochetti Juergen Schrezenmeir Ulrich R Foelsch Stefan Schreiber Massimo Campieri | 2006 | World Journal of Gastroenterology2006，12，37： | 3 |
| 2 | Ezrin/radixin/moesin: Versatile controllers of signaling molecules and of the cortical cytoskeleton显示文摘 | Verena Niggli Jérémie Rossy | 2007 | International Journal of Biochemistry and Cell Biology2007，，3： | 2 |
| 3 | Postoperative pain after transvaginal cholecystectomy: single-center, double-blind, randomized controlled trial显示文摘 | Dietmar H. Borchert Matthias Federlein Frauke Fritze-Büttner Jens Burghardt Britta Liersch-L?hn Yüksel Atas Verena Müller Oskar Rückbeil Stefan Wagenpfeil Stefan Gr?ber Klaus Gellert | 2014 | Surgical Endoscopy2014，，6： | 2 |
| 4 | Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro显示文摘 | Verena R Walter EH Johanna W | 2014 | Pulm Pharmacol Ther2014，28，2： | 1 |
| 5 | Ezrin/radixin/moesin: Versatile controllers of signaling molecules and of the cortical cytoskeleton显示文摘 | Verena Niggli Jérémie Rossy | 2007 | International Journal of Biochemistry and Cell Biology2007，，3： | 1 |
| 6 | RORγt+ hematopoietic cells are necessary for tumor cell proliferation during colitis‐associated tumorigenesis in mice显示文摘 | Maria Martin Rebecca K. Kesselring Balam Saidou Stefan M. Brunner Gabriela Schiechl Verena F. Mouris Anja K. Wege Petra Rümmele Hans J. Schlitt Edward K. Geissler Stefan Fichtner‐Feigl | 2015 | Eur. J. Immunol2015，，6： | 1 |
| 7 | Functional Characterization of Novel Mutations Affecting S urvivin ( BIRC 5)‐Mediated Therapy Resistance in Head and Neck Cancer Patients显示文摘 | Shirley K. Knauer Britta Unruhe Sarah Karczewski Rouven Hecht Verena Fetz Carolin Bier Sandra Friedl Barbara Wollenberg Ralph Pries Negusse Habtemichael Ulf‐Rüdiger Heinrich Roland H. Stauber | 2012 | Human Mutation2012，，： | 1 |
| 8 | Peri- ostin is up-regulated in high grade and high stage prostas cancer 显示文摘 | Verena Tischler Florian R Fritzschel Peter J Wild | 2010 | BMC Cancer2010，10，： | 1 |
| 9 | Arbuscular Mycorrhizas in Phosphate-Polluted Soil:Interrelations between Root Colonization and Nitrogen显示文摘 | Verena B Markus W Carsten R | 2011 | Plant Soil2011，343，12： | 1 |
| 10 | Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer显示文摘 | Verena Voelter Christoph Schuhmacher Raymonde Busch Christian Peschel J?rg Rüdiger Siewert Florian Lordick | 2004 | The Annals of Thoracic Surgery2004，，3： | 1 |
| 11 | Social Support and Welling - being in Adults Who Are Visually Impaired 显示文摘 | Verena R Cimarolli Kathrin Boerner | 2005 | Journal of Visual Impairment Blindness2005，，9： | 1 |
| 12 | Frequent cytolytic T-cell responses to peptide MAGE-A10254 262 in melanoma 显示文摘 | Danila V Valerie D Verena R G | 2001 | Cancer Research2001，61，2： | 1 |
| 13 | The association of circulating adiponectin levels with pancreatic cancer risk: A study within the prospective EPIC cohort显示文摘 | Verena A.Grote SabineRohrmann LaureDossus AlexandraNieters JytteHalkj?r AnneTj?nneland KimOvervad JakobStegger NathalieChabbert‐Buffet Marie‐ChristineBoutron‐Ruault Fran?oiseClavel‐Chapelon BirgitTeucher SusenBecker JukkaMontonen HeinerBoeing AntoniaTrich | 2012 | Int. J. Cancer2012，，10： | 1 |
| 14 | Impact of lactic acid bacteria on oxidative DNA damage in human derived colon cells显示文摘 | Verena J K Marian B Stidl R | 2008 | Food and Chemical Toxicology2008，46，4： | 1 |
| 15 | Proposal on theusage of conversion factors for fatty acids in fish and shellfish 显示文摘 | VERENA N DORIS R JACOB E | 2014 | Food Chemistry2014，153，： | 1 |
| 16 | Last line therapy with sorafenib in colorectal cancer: A retrospective analysis显示文摘AIM: To analyze the efficacy of last line sorafenib treatment in colorectal cancer patients. METHODS: All patients receiving chemotherapy for colorectal cancer in the outpatient clinic of the University of Mainz since 2006 were retrospectively analyzed for last line sorafenib exposure. Charts of identified patients were analyzed for clinic-pathological parameters, like data on gender, age, date of initial diagnosis, UICC stage, number and kind of the pretherapies, therapy start and end of sorafenib, sorafenib mediated treatment cessation, side effects, response rates, time to progression and overall survival. RESULTS: Ten patients with a median of 3.0 prior chemotherapy lines had received a last line sorafenib therapy either alone(10%) or in combination with 5-fluorouracil derivates(90%). All patients suffered from colorectal cancer stage UICC 4 and were routinely seen in 2-wk intervals in the oncology outpatient clinic. Median duration of treatment was 142.0 d. At 8 wk 80% of patients showed stable disease but we did not observe any remissions. Median time to progression was 140.5 d(4.7 mo), while median overall survival reached 176.5 d. One patient ceased treatment due to side effects. Reason for treatment stop was bleeding complication in one case and non-specified sorafenib intolerance in another case. Due to the retrospective approach we did not further quantify side effects.CONCLUSION: This retrospective analysis encourages further investigation of sorafenib in colorectal cancer last line therapy. | Ksenia Martchenko Irene Schmidtmann Thomas Thomaidis Verena Thole Peter R Galle Marc Becker Markus Mohler Thomas C Wehler Carl C Schimanski | 2016 | World Journal of Gastroenterology2016，22，23： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员